MGMaria Garcia-Casado

Maria Garcia-Casado

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Maria Garcia-Casado has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multiomic analysis of a pleural mesothelioma organoid biobank defines gene dependencies and therapeutic vulnerabilities

    by Jose Antonio Valer, Carmen Herranz-Ors, Claudia Arnedo-Pac, Marie Shamseddin, Joanna Obacz, Shriram G Bhosle, Maria Garcia-Casado, Sophie Brocklesby, Jessica Cantwell, Agnieszka E Andres, et al.

    Pleural mesothelioma (PM) remains an incurable cancer with few effective therapeutic options and limited understanding of its targetable dependencies, owing in part to a scarcity of clinically relevant, scalable models. Here, we describe establishment of an annotated biobank of 26 patient-derived PM organoids that faithfully recapitulate the clinical, genomic and histopathological landscapes of their parent tumours, including driver mutations, copy-number alterations and mutational signatures. By integrating these organoid models with a complementary collection of low-passage primary PM cell lines, we generate a functional precision oncology platform for PM. Genome-scale CRISPR-Cas9 screening across 23 patient-derived PM models uncovered 1,150 core fitness genes, including 638 not shared with pan-cancer core essentials, highlighting critical requirements for proteostasis, DNA repair, RNA processing and cell-cycle control. Parallel profiling of 106 compounds across 36 PM models revealed broad therapeutic vulnerabilities in proteostasis, growth signalling and epigenetic regulation. Beyond these shared vulnerabilities, both screens uncovered genotype-specific dependencies and drug responses linked to recurrent PM alterations. This functional map of shared and genotype-specific dependencies establishes patient-derived organoids as a scalable platform for precision therapeutic discovery in pleural mesothelioma